Catriona Yale Sells 9,074 Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO) Stock

Akero Therapeutics, Inc. (NASDAQ:AKRO - Get Free Report) insider Catriona Yale sold 9,074 shares of the business's stock in a transaction that occurred on Monday, December 16th. The shares were sold at an average price of $29.11, for a total value of $264,144.14. Following the transaction, the insider now directly owns 95,648 shares in the company, valued at approximately $2,784,313.28. This represents a 8.66 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website.

Catriona Yale also recently made the following trade(s):

• On Friday, November 15th, Catriona Yale sold 9,061 shares of Akero Therapeutics stock. The stock was sold at an average price of $27.73, for a total transaction of $251,261.53.
• On Friday, November 1st, Catriona Yale sold 15,485 shares of Akero Therapeutics stock. The shares were sold at an average price of $32.62, for a total transaction of $505,120.70.
• On Wednesday, October 30th, Catriona Yale sold 4,515 shares of Akero Therapeutics stock. The stock was sold at an average price of $32.53, for a total transaction of $146,872.95.
• On Monday, October 14th, Catriona Yale sold 6,136 shares of Akero Therapeutics stock. The stock was sold at an average price of $30.03, for a total transaction of $184,264.08.
• On Friday, September 20th, Catriona Yale sold 5,500 shares of Akero Therapeutics stock. The shares were sold at an average price of $27.65, for a total value of $152,075.00.

Akero Therapeutics Trading Down 6.2 %

Shares of NASDAQ AKRO traded down $1.90 during trading hours on Wednesday, reaching $28.71. The stock had a trading volume of 742,147 shares, compared to its average volume of 842,461. Akero Therapeutics, Inc. has a 52-week low of $15.32 and a 52-week high of $37.00. The firm has a market cap of $2.00 billion, a price-to-earnings ratio of -7.66 and a beta of -0.23. The business's fifty day moving average price is $30.91 and its two-hundred day moving average price is $27.36. The company has a current ratio of 17.25, a quick ratio of 17.25 and a debt-to-equity ratio of 0.05.

Akero Therapeutics (NASDAQ:AKRO - Get Free Report) last issued its earnings results on Friday, November 8th. The company reported ($1.05) earnings per share for the quarter, missing the consensus estimate of ($0.90) by ($0.15). Analysts expect that Akero Therapeutics, Inc. will post -3.96 EPS for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts recently issued reports on AKRO shares. Citigroup assumed coverage on Akero Therapeutics in a research note on Monday, November 18th. They set a "buy" rating and a $65.00 price target for the company. HC Wainwright reiterated a "buy" rating and issued a $50.00 target price on shares of Akero Therapeutics in a research note on Monday, November 18th. One equities research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $46.83.

Institutional Trading of Akero Therapeutics

A number of hedge funds have recently added to or reduced their stakes in the business. Wellington Management Group LLP raised its holdings in shares of Akero Therapeutics by 54.4% in the 3rd quarter. Wellington Management Group LLP now owns 7,896,632 shares of the company's stock valued at $226,554,000 after purchasing an additional 2,782,029 shares in the last quarter. Point72 Asset Management L.P. purchased a new position in Akero Therapeutics during the third quarter valued at approximately $37,392,000. RTW Investments LP raised its stake in Akero Therapeutics by 9.0% in the third quarter. RTW Investments LP now owns 5,919,435 shares of the company's stock worth $169,829,000 after buying an additional 487,450 shares in the last quarter. Long Focus Capital Management LLC raised its stake in Akero Therapeutics by 119.0% in the second quarter. Long Focus Capital Management LLC now owns 719,604 shares of the company's stock worth $16,882,000 after buying an additional 391,000 shares in the last quarter. Finally, Janus Henderson Group PLC lifted its holdings in Akero Therapeutics by 2.9% during the third quarter. Janus Henderson Group PLC now owns 7,077,478 shares of the company's stock worth $203,053,000 after buying an additional 201,225 shares during the period.

Akero Therapeutics Company Profile

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.